First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies

Summary

This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts an accelerated titration for the first dose level, followed by BOIN design to identify the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC101.

Timeline

Start

2025-09-23

Primary completion

2027-07-01

Completion

2028-07-01

Drugs

Indications

No indication recorded.